Post-finasteride syndrome - does it really exist?

Area of Science:

• Pharmacology
• Endocrinology
• Dermatology

Background:

• 5α-steroid reductase inhibitors treat androgen-dependent conditions such as prostate diseases and androgenic alopecia.
• Finasteride and dutasteride are common inhibitors with known adverse events including sexual dysfunction and mood changes.
• Prolonged use may lead to persistent side effects, termed post-finasteride syndrome (PFS).

Purpose of the Study:

• To highlight the characteristics and implications of post-finasteride syndrome (PFS).
• To emphasize the need for wider recognition of PFS symptoms, incidence, and course.
• To advocate for reconsidering drug indications and personalizing treatment based on PFS knowledge.

Main Methods:

• Literature review on 5α-steroid reductase inhibitors and their side effects.
• Analysis of reported cases and characteristics of post-finasteride syndrome.
• Discussion of the impact of PFS on patient quality of life and treatment decisions.

Main Results:

• Post-finasteride syndrome (PFS) is a distinct iatrogenic syndrome with persistent side effects.
• PFS can occur in susceptible individuals even after low doses and may persist post-discontinuation.
• The deterioration in quality of life associated with PFS may not be justified by the drug's benefits.

Conclusions:

• Wider recognition of PFS is essential for patient safety and informed consent.
• Understanding PFS allows for more personalized treatment and reconsideration of drug indications.
• Improved knowledge of PFS will facilitate better patient education and management.